Related Experiment Video
Updated: May 18, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
New perspectives in the therapy of castration resistant prostate cancer
Pasquale Rescigno1, Carlo Buonerba, Joaquim Bellmunt
1Genitourinary Cancer Section, Medical Oncology Division, Department of Endocrinology and Oncology, University Federico II, Napoli, Italy. giuseppedilorenzoncol@hotmail.com
Abstract:
Prostate Cancer is the most commonly diagnosed malignancy and the second leading cause of cancer-related death in men in the Western World. Docetaxel-based chemotherapy has been the mainstay of treatment until a few years ago for metastatic castration resistant prostatic cancer (mCRPC). Recently, a broad range of therapeutic options has become available for mCRPC in a variety of settings, including chemotherapeutic agents (cabazitaxel), androgen synthesis inhibitors (abiraterone acetate), androgen receptor (AR) inhibitors (enzalutamide) and immunotherapy (sipuleucel-T). Multiple novel targeted agents are at an advanced stage of experimentation, including androgen synthesis inhibitors (TAK700), AR inhibitors (ARN509), radiopharmaceuticals (radium-223) and immunotherapeutic agents (poxvirus-based vaccine, ipilimumab). This review describes in detail the latest results obtained with a the most promising agents in prostate cancer, with a focus on CRPC biology and mechanism of resistance to anti-neoplastic treatment.
More Related Videos
Related Concept Videos
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistent Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

